Redefining the systemic inflammatory response

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 13, Issue 2, 2009, Pages 87-94

  Landis, R Clive ^a  

^a UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

Coagulation; Inflammatory response; Organ injury

Indexed keywords

ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; ANTITHROMBIN; APROTININ; CLOPIDOGREL; CYTOKINE; FIBRINOLYTIC AGENT; KALLIKREIN; OXYGEN RADICAL; PEXELIZUMAB; PROTEINASE; SCH 530348; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

BLEEDING; BLOOD CLOTTING; BLOOD VESSEL; BYPASS SURGERY; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPREHENSION; DEGRANULATION; ENZYME RELEASE; FIBRINOLYSIS; HEMOLYSIS; HUMAN; IMMUNE RESPONSE; INJURY; INTERVENTION STUDY; ISCHEMIA; KIDNEY FAILURE; LEUKOCYTE ACTIVATION; MEASUREMENT; MONITORING; MONONUCLEAR CELL; NONHUMAN; ORGAN INJURY; OXIDATIVE STRESS; PARAMETER; PERFUSION; PROTEIN SYNTHESIS; REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THORAX SURGERY;

BLOOD COAGULATION; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION; FIBRINOLYSIS; HUMANS; INFLAMMATION MEDIATORS; OXIDATIVE STRESS; POSTOPERATIVE COMPLICATIONS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 68349103358     PISSN: 10892532     EISSN: None     Source Type: Journal    
DOI: 10.1177/1089253209337743     Document Type: Review

References (78)

1. Butler J., Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 1993 ; 55: 552-559.
2. Boisclair MD, Lane DA, Philippou H., Sheikh S., Hunt B. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F1 + 2. Thromb Haemost. 1993 ; 70: 253-258.
3. Brister SJ, Ofosu FA, Buchanan MR Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant ? Thromb Haemost. 1993 ; 70: 259-262.
4. Monroe DM, Hoffman M., Roberts HR Platelets and thrombin generation. Arterioscler Thromb Vasc Biol. 2002 ; 22: 1381-1389.
5. Ferraris VA, Ferraris SP, Singh A., et al. The platelet thrombin receptor and postoperative bleeding. Ann Thorac Surg. 1998 ; 65: 352-358.
6. Kaplanski G., Fabrigoule M., Boulay V., et al. Thrombin induces endothelial type II activation in vitro: IL-1 and TNF-alpha-independent IL-8 secretion and E-selectin expression. J Immunol. 1997 ; 158: 5435-5441.
7. Kaplanski G., Marin V., Fabrigoule M., et al. Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106). Blood. 1998 ; 92: 1259-1267.
8. Kamiya T., Katayama Y., Kashiwagi F., Terashi A. The role of bradykinin in mediating ischemic brain edema in rats. Stroke. 1993 ; 24: 571-575.
9. Wachtfogel YT, Hack CE, Nuijens JH, et al. Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation. Am J Physiol. 1995 ; 268 (3, pt 2). H1352 - H1357.
10. Lidington EA, Haskard DO, Mason JC Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury. Blood. 2000 ; 96: 2784-2792.
11. Wojciak-Stothard B., Potempa S., Eichholtz T., Ridley AJ Rho and Rac but not Cdc42 regulate endothelial cell permeability. J Cell Sci. 2001 ; 114 (pt 7). 1343-1355.
12. Day JR, Taylor KM, Lidington EA, et al. Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1. J Thorac Cardiovasc Surg. 2006 ; 131: 21-27.
13. Poullis M., Manning R., Laffan M., Haskard DO, Taylor KM, Landis RC The antithrombotic effect of aprotinin: actions mediated via the protease activated receptor 1. J Thorac Cardiovasc Surg. 2000 ; 120: 370-378.
14. Martorell L., Martinez-Gonzalez J., Rodriguez C., Gentile M., Calvayrac O., Badimon L. Thrombin and protease-activated receptors (PARs) in atherothrombosis. Thromb Haemost. 2008 ; 99: 305-315.
15. Moliterno DJ Results of a multinational randomized, double-blind, placebo-controlled study of a novel thrombin receptor antagonist SCH 530348 in percutaneous coronary intervention. Paper presented at: ACC Meeting 2007 ; Abstract 2402-9; 2007.
16. Ofosu FA, Freedman J., Dewar L., Song Y., Fenton JW A trypsin-like platelet protease propagates protease-activated receptor-1 I cleavage and platelet activation. Biochem J. 1998 ; 336 (pt 2). 283-285.
17. Day JR, Punjabi PP, Randi AM, Haskard DO, Landis RC, Taylor KM Clinical inhibition of the seven-transmembrane thrombin receptor (PAR1) by intravenous aprotinin during cardiothoracic surgery. Circulation. 2004 ; 110: 2597-2600.
18. Ofosu FA, Dewar L., Craven SJ, et al. Coordinate activation of human platelet protease-activated receptor-1 and -4 in response to subnanomolar alpha-thrombin. J Biol Chem. 2008 ; 283: 26886-26893.
19. Jones HM, Matthews N., Vaughan RS, Stark JM Cardiopulmonary bypass and complement activation. Involvement of classical and alternative pathways. Anaesthesia. 1982 ; 37: 629-633.
20. McCarthy PM, Yared JP, Foster RC, Ogella DA, Borsh JA, Cosgrove DM III. A prospective randomized trial of Duraflo II heparin-coated circuits in cardiac reoperations. Ann Thorac Surg. 1999 ; 67: 1268-1273.
21. Eisses MJ, Geiduschek JM, Jonmarker C., Cohen GA, Chandler WL Effect of polymer coating (poly 2-methoxyethylacrylate) of the oxygenator on hemostatic markers during cardiopulmonary bypass in children. J Cardiothorac Vasc Anesth. 2007 ; 21: 28-34.
22. Ask A., Holt D., Smith L. In vivo comparison study of FDA-approved surface-modifying additives and poly-2-methoxyethylacrylate circuit surfaces coatings during cardiopulmonary bypass. J Extra Corpor Technol. 2006 ; 38: 27-32.
23. Bical OM, Fromes Y., Gaillard D., et al. Comparison of the inflammatory response between miniaturized and standard CPB circuits in aortic valve surgery. Eur J Cardiothorac Surg. 2006 ; 29: 699-702.
24. Shann KG, Likosky DS, Murkin JM, et al. An evidence-based review of the practice of cardiopulmonary bypass in adults: a focus on neurologic injury, glycemic control, hemodilution, and the inflammatory response. J Thorac Cardiovasc Surg. 2006 ; 132: 283-290.
25. Verrier ED, Shernan SK, Taylor KM, et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA. 2004 ; 291: 2319-2327.
26. Mathew JP, Shernan SK, White WD, et al. Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery. Stroke. 2004 ; 35: 2335-2339.
27. Haverich A., Shernan SK, Levy JH, et al. Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients. Ann Thorac Surg. 2006 ; 82: 486-492.
28. McBride WT, Armstrong MA, Crockard AD, McMurray TJ, Rea JM Cytokine balance and immunosuppressive changes at cardiac surgery: contrasting response between patients and isolated CPB circuits. Br J Anaesth. 1995 ; 75: 724-733.
29. Andrew D., Shock A., Ball E., Ortlepp S., Bell J., Robinson M. KIM185, a monoclonal antibody to CD18 which induces a change in the conformation of CD18 and promotes both LFA-1- and CR3-dependent adhesion. Eur J Immunol. 1993 ; 23: 2217-2222.
30. Rothlein R., Kishimoto TK, Mainolfi E. Cross-linking of ICAM-1 induces co-signaling of an oxidative burst from mononuclear leukocytes. J Immunol. 1994 ; 152: 2488-2495.
31. Shappell SB, Toman C., Anderson DC, Taylor AA, Entman ML, Smith CW Mac-1 (CD11b/CD18) mediates adherence-dependent hydrogen peroxide production by human and canine neutrophils. J Immunol. 1990 ; 144: 2702-2711.
32. Bywaters EG 50 years on: the crush syndrome. BMJ. 1990 ; 301: 1412-1415.
33. Christen S., Finckh B., Lykkesfeldt J., et al. Oxidative stress precedes peak systemic inflammatory response in pediatric patients undergoing cardiopulmonary bypass operation. Free Radic Biol Med. 2005 ; 38: 1323-1332.
34. Tanaka K., Kanamori Y., Sato T., et al. Administration of haptoglobin during cardiopulmonary bypass surgery. ASAIO Trans. 1991 ; 37: M482 - M483.
35. Davis CL, Kausz AT, Zager RA, Kharasch ED, Cochran RP Acute renal failure after cardiopulmonary bypass in related to decreased serum ferritin levels. J Am Soc Nephrol. 1999 ; 10: 2396-2402.
36. Nakhoul FM, Zoabi R., Kanter Y., et al. Haptoglobin phenotype and diabetic nephropathy. Diabetologia. 2001 ; 44: 602-604.
37. Fagoonee S., Gburek J., Hirsch E., et al. Plasma protein haptoglobin modulates renal iron loading. Am J Pathol. 2005 ; 166: 973-983.
38. Kato GJ, McGowan V., Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood. 2006 ; 107: 2279-2285.
39. Minneci PC, Deans KJ, Zhi H., et al. Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. J Clin Invest. 2005 ; 115: 3409-3417.
40. Jegger D., Horisberger J., Jachertz M., et al. A novel device for reducing hemolysis provoked by cardiotomy suction during open heart cardiopulmonary bypass surgery: a randomized prospective study. Artif Organs. 2007 ; 31: 23-30.
41. Leal-Noval SR, Rincon-Ferrari MD, Garcia-Curiel A., et al. Transfusion of blood components and postoperative infection in patients undergoing cardiac surgery. Chest. 2001 ; 119: 1461-1468.
42. Spiess BD, Royston D., Levy JH, et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion. 2004 ; 44: 1143-1148.
43. Michalopoulos A., Tzelepis G., Dafni U., Geroulanos S. Determinants of hospital mortality after coronary artery bypass grafting. Chest. 1999 ; 115: 1598-1603.
44. Koch CG, Li L., Duncan AI, et al. Transfusion in coronary artery bypass grafting is associated with reduced long-term survival. Ann Thorac Surg. 2006 ; 81: 1650-1657.
45. Furnary AP, Wu Y., Hiratzka LF, Grunkemeier GL, Page US III. Aprotinin does not increase the risk of renal failure in cardiac surgery patients. Circulation. 2007 ; 116 (11, suppl). 1127-1133.
46. Wachtfogel YT, Kucich U., Hack CE, et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg. 1993 ; 106: 1-9.
47. Anttila V., Hagino I., Iwata Y., et al. Aprotinin improves cerebral protection: evidence from a survival porcine model. J Thorac Cardiovasc Surg. 2006 ; 132: 948-953.
48. Pruefer D., Makowski J., Dahm M., et al. Aprotinin inhibits leukocyte-endothelial cell interactions after hemorrhage and reperfusion. Ann Thorac Surg. 2003 ; 75: 210-215.
49. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006 ; 354: 353-365.
50. Mangano DT, Miao Y., Vuylsteke A., et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA. 2007 ; 297: 471-479.
51. Shaw AD, Stafford-Smith M., White WD, et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med. 2008 ; 358: 784-793.
52. Henry DA, Moxey AJ, Carless PA, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2001 ;(1). CD001886.
53. Sedrakyan A., Treasure T., Elefteriades JA Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg. 2004 ; 128: 442-448.
54. Rossignol P., Ho-Tin-Noe B., Vranckx R. et al. Protease nexin-1 inhibits plasminogen activation-induced apoptosis of adherent cells. J Biol Chem. 2004 ; 279: 10346-10356.
55. Kang HM, Kalnoski MH, Frederick M., Chandler WL The kinetics of plasmin inhibition by aprotinin in vivo. Thromb Res. 2005 ; 115: 327-340.
56. Junge CE, Sugawara T., Mannaioni G., et al. The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. Proc Natl Acad Sci U S A. 2003 ; 100: 13019-13024.
57. Hall KD, Landis RC Plasmin but not thrombin activates A172 glial cells via serine proteolytic cleavage of preoteaseactivated receptor (PAR)1. Heart Surg Forum. In press.
58. Moliterno DJ, Becker RC, Jennings LK, et al. Results of a multinational randomized, double-blind, placebo-controlled study of a novel thrombin receptor antagonist SCH 530348 in percutaneous coronary intervention. Paper presented at: American College of Cardiology Meeting ; March 24, 2007 ; New Orleans, LA.
59. Poston RS, Gu J., Brown JM, et al. Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2006 ; 131: 122-130.
60. Manchio JV, Gu J., Romar L., et al. Disruption of graft endothelium correlates with early failure after off-pump coronary artery bypass surgery. Ann Thorac Surg. 2005 ; 79: 1991-1998. (Pubitemid 40804176)
61. Wolberg AS Thrombin generation and fibrin clot structure. Blood Rev. 2007 ; 21: 131-142.
62. Hammon JW, Stump DA, Butterworth JF, et al. Single crossclamp improves 6-month cognitive outcome in high-risk coronary bypass patients: the effect of reduced aortic manipulation. J Thorac Cardiovasc Surg. 2006 ; 131: 114-121.
63. Brown EN, Burris NS, Gu J., et al. Thinking inside the graft: applications of optical coherence tomography in coronary artery bypass grafting. J Biomed Opt. 2007 ; 12: 051704.
64. Burris NS, Brown EN, Grant M., et al. Optical coherence tomography imaging as a quality assurance tool for evaluating endoscopic harvest of the radial artery. Ann Thorac Surg. 2008 ; 85: 1271-1277.
65. Soderstrom T., Hedner U., Arnljots B. Active site-inactivated factor VIIa prevents thrombosis without increased surgical bleeding: topical and intravenous administration in a rat model of deep arterial injury. J Vasc Surg. 2001 ; 33: 1072-1079.
66. De Somer F., Van BY, Caes F., et al. Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2002 ; 123: 951-958.
67. McNeely TB, Griffith MJ The anticoagulant mechanism of action of heparin in contact-activated plasma: inhibition of factor X activation. Blood. 1985 ; 65: 1226-1231.
68. Spanier TB, Oz MC, Minanov OP, et al. Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog. J Thorac Cardiovasc Surg. 1998 ; 115: 1179-1188.
69. Landis RC, Brown JR, Murkin JM, Likosky DS, Baker RA An evidence-based review of pharmacological interventions to limit the systemic inflammatory response in cardiac surgery. Heart Surg Forum. In press.
70. Clark WM, Madden KP, Rothlein R., Zivin JA Reduction of central nervous system ischemic injury in rabbits using leukocyte adhesion antibody treatment. Stroke. 1991 ; 22: 877-883.
71. Mori E., del Zoppo GJ, Chambers JD, Copeland BR, Arfors KE Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons. Stroke. 1992 ; 23: 712-718.
72. Kalman J., Juhasz A., Bogats G., et al. Elevated levels of inflammatory biomarkers in the cerebrospinal fluid after coronary artery bypass surgery are predictors of cognitive decline. Neurochem Int. 2006 ; 48: 177-180.
73. Ramlawi B., Rudolph JL, Mieno S., et al. C-Reactive protein and inflammatory response associated to neurocognitive decline following cardiac surgery. Surgery. 2006 ; 140: 221-226.
74. Asimakopoulos G., Thompson R., Nourshargh S., et al. An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation. J Thorac Cardiovasc Surg. 2000 ; 120: 361-369.
75. Hill GE, Pohorecki R., Alonso A., Rennard SI, Robbins RA Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth Analg. 1996 ; 83: 696-700.
76. Kaneider NC, Leger AJ, Kuliopulos A. Therapeutic targeting of molecules involved in leukocyte-endothelial cell interactions. FEBS J. 2006 ; 273: 4416-4424.
77. Kaneider NC, Agarwal A., Leger AJ, Kuliopulos A. Reversing systemic inflammatory response syndrome with chemokine receptor pepducins. Nat Med. 2005 ; 11: 661-665.
78. Landis RC, Arrowsmith JE, Baker RA, et al. Consensus statement: defining the minimal criteria for reporting the systemic inflammatory response to cardiopulmonary bypass. Heart Surg Forum. 2008 ; 11: E316 - E322.